The Business Development Fundamentals Course is offered as a continuing education program for biopharmaceutical, academic and not for profit professionals as part of BIO’s executive training course series. The three-day course is instructed by experts in the areas of finance, transactional and intellectual property law, licensing and alliance management, management consulting and strategic commercial development. The majority have held positions of increasing responsibility in the life sciences industry ranging from biotherapeutics to diagnostics and medical devices.
2018 Business Development Fundamentals Faculty:
Anjan Aralihalli, Chief Business Officer, GLyPharma Therapeutic; Venture Partner, CTI Life Sciences Fund II
Anjan or "AJ" Aralihalli is currently Chief Business Officer of GLyPharma Therapeutic, a Canadian biotechnology company focused on rare GI disorders. He is also a Venture Partner at CTI Life Sciences, a leading Canadian venture fund and is a member of a NYC based angel investment group called Mid-Atlantic Bio Angels (MABA). AJ is also a corporate fundraiser for two ALS charities, Wings Over Wall Street (a division of the Muscular Dystrophy Association) and The Robert Packard Center for ALS Research at Johns Hopkins University.
Previously, he worked at a variety of biotechs and pharma companies including Neurochem, Abbott, Sanofi, Shionogi and ActoGeniX. He has 20+ years of international experience across a number of functions including investor relations, corporate development, venture and angel financing, in & out-licensing, strategic alliances, alliance management, new product development, sales, marketing, & clinical trial management.
He received his BSc from Concordia University, MBA from Queen's University (both in Canada) and is currently completing his MSc at Johns Hopkins University.
Mark Cooper, Senior VP, Science and Medical Affairs, Copernicus Therapeutics, Inc.
After receiving his PhD in Plant Pathology from Rutgers University, New Jersey (USA) in 1977, Dr. Bor-Fuei “Apo” Huang conducted his postdoctoral research at the Fox Chase Cancer Center in Philadelphia (USA). From 1979, he worked in the US as researcher and program directors in various AgBiotech organizations including Boyce Thompson Institute at Cornell University, AgBiotech R&D center at Allied Signal Corp. and Enichem Americas…. In 2002, he moved back to his native country Taiwan to join the Development Center for Biotechnology (DCB) switching from AgBiotech to drug development and from research to business development and management. With increasing responsibility he was the Director of International Collaboration, Director of Business Development and the Director General of Industry Promotion Division with a team of 70+ members conducting industrial information research, tech transfer/licensing and commercialization, business planning and development, private public partnership and international collaboration. After his retirement in 2012, he has been consulting with companies that are interested in developing biotech business with Taiwan. Since 2009 he has been the Secretary General of the Taiwan Bio Industry Organization, the largest biotech Association in Taiwan. He also has an MBA degree from the Pennsylvania State University, USA.
Kathleen Denis, PhD, Founding Director, Office of Technology Transfer, The Rockefeller University
Kathleen A. Denis, Ph.D. is the Associate Vice President of Technology Transfer at The Rockefeller University, a premier biomedical research institution located in New York City. Managing the intellectual assets of the University, she works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. Formerly a consultant specializing in the management of intellectual assets in the life sciences, she worked with academic and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses.
Dr. Denis is active in numerous professional organizations and speaks frequently about early stage technology evaluation, formation of start-up companies, conflict of interest and other issues of academic technology transfer. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the Board of Directors of the Association of University Technology Managers (AUTM) and the Pennsylvania Biotechnology Association.
From 1995 through 1998 Dr. Denis was Vice President, Technology Development at Allegheny Health, Education and Research Foundation. She managed the intellectual property and research assets of the Medical College of Pennsylvania and Hahnemann University, as well as Allegheny General Hospital and Allegheny Singer Research Institute. Responsibilities of this position included the evaluation and marketing of technologies, building collaborative relationships with the biomedical and biopharmaceutical communities and promotion of economic development in Pennsylvania.
Dr. Denis was a Director at the University of Pennsylvania Center for Technology Transfer from 1991 to 1995, where she managed a large portfolio of biotechnology and pharmaceutical related technologies. Previously, she was an investigator at the Molecular Biology Institute at UCLA for eight years, and a Senior Scientist at Specialty Laboratories, Inc. She has over thirty scientific publications.
Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in Human Genetics from University of Texas Medical Branch at Galveston and an undergraduate degree in genetics from Cornell University.
Philippe Nore, Co-founder and CEO, MiNDERA Dx
Philippe Nore is an experienced executive specialized in clinical diagnostics, genomics and life science tools. He currently is CEO and co-founder of MiNDERA, an early stage clinical diagnostics company. Before founding MiNDERA, Philippe Nore was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the Ventana Digital Pathology products (hardware, software, algorithms to score assays) in the cancer diagnostics market, including global P&L responsibility. During his tenure at Roche he has successfully launched several FDA-approved products.
Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. Earlier, he worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business Unit and led the Next-Generation Sequencing taskforce. He also spent 7 years at Bain & Company where he consulted for Fortune 500 companies.
Philippe has negotiated numerous licensing and acquisition transactions in his career and has deep expertise in strategic and financial valuation of biotech assets.
Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.
Pauline Jen Ryan, Partner, Red Sky Partners
At Red Sky, Pauline Jen Ryan serves clients by taking on interim C-level roles (CEO, CBO, COO) or acting as an advisor on general corporate and business development matters. Her particular expertise is with small- to mid-size biotech companies, including startups and companies leveraging “virtual” operating models. Pauline has served as virtual CBO for several oncology companies. Most recently, Pauline served as interim co-CEO of Harbour Antibodies where she led the management of consultants/employees, started a US subsidiary and completed numerous business development transactions.
In addition to her work at Red Sky, Pauline is currently CEO of Verik Bio, a biotech startup pioneering T cell-based immunotherapy for solid tumor cancers. Prior to joining Red Sky Partners, Pauline helped lead investor Healthcare Ventures raise a $45M Series A round to launch Proteostasis Therapeutics. In addition to setting intellectual property and business development strategy, she was responsible for establishing and growing all business operations functions such as finance, human resources and communications from launch to 50 employees. Previously, Pauline was Senior Vice President, Corporate Development & Operations at ImmunoGen, where secured the corporate partnership with Genentech that created Kadcyla® for breast cancer. She headed corporate strategic planning, business development and alliance management during her tenure there and was also responsible for human resources, manufacturing, and program management during growth and transition stages. She was responsible for raising over $150M in corporate partnerships and was also instrumental in completing a $125M secondary offering.
Pauline is a member of The Boston Club and also volunteers as a Trustee of the Advanced Math and Science Academy Charter School, currently serving as Chair. She was previously a member of the Board of Directors for Lumio, a startup incubating at the Martin Trust Center for Entrepreneurship at MIT, and also for Solmap Pharmaceuticals (acquired by Forma Therapeutics). Pauline was also a founding member of the Biotechnology Industry Organization’s Business Development Advisory Committee and launched the BIO Business Development Fundamentals Course in 2003.
Pauline has an MBA from the Kellogg Graduate School of Management at Northwestern University, and a BA in Psychology from Northwestern University.
Kate Scrable, Director of Alliance Management, Genentech Partnering
Kate Skrable has over 20+ years in business development and alliance management. Kate approaches alliance management with dedication, leadership, and advocacy. She has been with Genentech Partnering for over 6 years. During her tenure she has managed dozens of research, development, and commercial partnerships and collaborations. Prior to joining Genentech Partnering, Kate worked in a variety of licensing, alliance management, and mergers/acquisitions roles at Valeant, Perlegen, and Connetics.
Kate holds an MBA from Santa Clara University, a MS in Physiology from University of Arizona, and BS from Loyola Marymount University. She is also a member of ASAP (Association of Strategic Alliance Professionals).
John Selig, Managing Partner, WaveEdge Capital LLC
John Selig is a Managing Partner and co-founder of WaveEdge Capital LLC, a healthcare investment bank advising companies on M&A, licensing and finance strategy. He was formerly Managing Director and co-head of the Life Sciences Group at Woodside Capital Partners.
Prior to joining Woodside, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small cap biopharmaceutical, medical device and diagnostics companies on M&A and licensing strategies, portfolio management, valuation and strategic direction. While at KR, John led a partnership deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.
Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised numerous Fortune 500 companies in life sciences and other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal & Manges LLP where he focused on M&A and corporate finance.
John holds a JD from Stanford Law School and a BA from Brown University.
Robert Silverman, Senior Vice President and General Counsel, Concert Pharmaceuticals
Kyle E. Murphy is the Managing Director and Founder of KMG Japan. Kyle has lived in Japan for a significant portion of his adult life. His business has involved working with Japanese and Asian Life Science and healthcare businesses for over 30 years. Kyle speaks Japanese and built a strong network of contacts in both the healthcare industry and government administration. He has represented over 100 clients and successfully structured numerous alliances between Japanese, Asian and foreign companies. Prior to founding KMG Japan, Kyle served as the First Commercial Secretary in the US Embassy in Tokyo where he managed all trade negotiations and activities related to bringing US companies into the Japanese healthcare market. Kyle began his career in the healthcare industry with business development and marketing positions at Schering-Plough in Osaka, Japan and SmithKline in the US.
Patricia Sinatra, Managing Director, Vector Strategic Advisors, Program Director, BIO Business Development Fundamental Courses
Ms Sinatra has directed and instructed the BIO BD Fundamentals course since 2007. She is also Chair of the Next Generation Biotherapeutics Educational Session for the 2018 BIO meeting. She possesses more than 20 years of biopharmaceuticals industry experience where her expertise blends licensing, alliance management with a foundation in strategic marketing, corporate and technology positioning and market research. She has negotiated a variety of deal structures with big pharma, biotech and academia. She is currently Managing Director of Vector Strategic Advisors LLC. Previously, she held senior business development, marketing, and strategy positions for Telomere Diagnostics, Sutro Biopharma (previously Fundamental Applied Biology), Dynavax Technologies, Abgenix (Amgen), Matrix (Novartis), SEQUUS/ALZA (JNJ), FCB Healthcare and Smithkline Beecham (GSK). She is also an advisor for the UCSF Start Up 101 and the California Life Science Institute’s FAST programs.
Earlier in her career she was a Visiting Assistant Professor of Biology at the University of Dallas and taught a continuing education module for physicians and nurses for the Department of Health in Dallas, TX. Ms. Sinatra received her undergraduate degree from the State University of New York and conducted PhD studies in Microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences. She has also conducted extensive continuing education courses in marketing, finance and accounting at UC Berkeley.
Ken Weber, PhD, Partner, Kilpatrick Townsend & Stockton LLP
Kenneth Weber, Ph.D., focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.
Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.
The goal of the course is to provide an intensive and comprehensive educational foundation on the core skills that are needed to be a successful licensing executive in the life sciences industry and a networking platform for attendees.
- The Role of Intellectual Property In Creating Value
- Strategic Alliances - Partner and technology opportunity assessment and process, types of deal structures, term sheet development, the role of alliance management
- Financial Modeling and Valuation in Licensing
- Contracts Used in Licensing (CDAs, MTAs, Sponsored Research Agreements, Definitive Agreements )
- Negotiation and Communication Strategies
- University Technology Transfer and it’s Role in IP Creation
- Case Study
Who should attend?
- Professionals who are new to business development and licensing or who have limited deal experience.
- Alliance management, R&D, legal, marketing or academic professionals who desire to learn more about licensing within their organizations or as a career opportunity.
- Entrepreneurs who have not been exposed to licensing or M&A type transactions but recognize it as a critical strategic initiative for their business.
- Professionals interested in a comprehensive refresher course in licensing.
If you have any questions about the program, please contact Patricia Sinatra at firstname.lastname@example.org.
*Content is subject to modification.